Currently available prognostic scoring systems in MDS
| System . | Blood . | Marrow . | Patient . | Comments . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Hgb . | PLTs . | ANC . | Blasts . | Cyto . | Age . | Txn . | PS . | ||
| IPSS | + | + | + | + | + | + | Has been revised now (2012) using the same prognostic parameters (number and depth or cytopenias, marrow blast percentage [more granular] and karyotype), was able to reclassify nearly 25% of lower-risk MDS patients into a higher-risk category | ||
| WPSS | + | + | + | Time dependent which is useful over the course of patient's disease | |||||
| MDS LR | + | + | + | + | + | + | May be applied specifically to lower-risk disease with more variables | ||
| MDAPSS | + | + | + | + | + | + | + | Contains more clinical variables, especially age and transfusion burden, which could upstage a patient | |
| FPSS | + | + | + | Higher-risk disease and includes azacytidine-treated patients, likely is not useful in lower-risk patients, even for upstaging | |||||
| IPSS-R | + | + | + | + | + | + | Used most commonly at diagnosis and for clinical trial eligibility, limitations discussed in text | ||
| System . | Blood . | Marrow . | Patient . | Comments . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Hgb . | PLTs . | ANC . | Blasts . | Cyto . | Age . | Txn . | PS . | ||
| IPSS | + | + | + | + | + | + | Has been revised now (2012) using the same prognostic parameters (number and depth or cytopenias, marrow blast percentage [more granular] and karyotype), was able to reclassify nearly 25% of lower-risk MDS patients into a higher-risk category | ||
| WPSS | + | + | + | Time dependent which is useful over the course of patient's disease | |||||
| MDS LR | + | + | + | + | + | + | May be applied specifically to lower-risk disease with more variables | ||
| MDAPSS | + | + | + | + | + | + | + | Contains more clinical variables, especially age and transfusion burden, which could upstage a patient | |
| FPSS | + | + | + | Higher-risk disease and includes azacytidine-treated patients, likely is not useful in lower-risk patients, even for upstaging | |||||
| IPSS-R | + | + | + | + | + | + | Used most commonly at diagnosis and for clinical trial eligibility, limitations discussed in text | ||
The prognostic scoring systems are listed in order of publication with annotations on the variables included and comments on their use in lower risk disease.
Cyto, cytogenetics; FPSS, French Prognostic Scoring System; MDAPSS, MD Anderson Prognostic Scoring System; MDS LR, scoring system for patients with lower-risk MDS; PS, performance status; Txn, transfusions; WPSS, WHO Classification-Based Prognostic Scoring System.